Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta syndrome (APDS) in the second half of 2021.
Novartis was developing the selective PI3Kδ inhibitor, also known as CDZ173, in APDS in the belief it can increase the low white blood cell levels that characterize the rare genetic disease. However, the Swiss big pharma has decided to shift strategies in the middle of a phase 2/3 trial, offloading the rights to Pharming in return for a small upfront fee plus milestones and royalties.
Pharming’s interest in leniolisib relates to the overlap between the physicians that may prescribe the drug and its existing commercial asset, hereditary angioedema treatment Ruconest. Both drugs will be prescribed by immunologists, enabling Pharming to use existing infrastructure to push leniolisib.
“The license of CDZ173 is our first step towards building off the commercial success of Ruconest in HAE to grow and diversify our portfolio,” Pharming CEO Sijmen de Vries said in a statement. “It is a perfect strategic fit for our existing medical and commercial infrastructure.”
Novartis moved leniolisib into the open-label dose-escalation portion of a phase 2/3 trial in 2015 and presented long-term follow-up data on six patients late last year. The readout suggested leniolisib does not cause diarrhea or other side effects associated with mTOR or other PI3K inhibitors. Half of the patients stopped taking immunoglobulin following the normalization of B cell function.
Pharming hopes to build on these results to create a data set capable of persuading regulators to approved the drug, starting by working with Novartis to complete enrollment in the second part of the phase 2/3 trial.
GlaxoSmithKline also has a treatment for APDS in development. An inhaled formulation of that drug, another selective PI3Kδ inhibitor known as GSK2269557, is being tested in a 20-patient phase 2 trial.
By: Nick Paul Taylor
Source: Fierce Biotech
The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.
According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.
Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.
342795 8452Its always very good to learn ideas like you share for blog posting. As I just started posting comments for weblog and facing dilemma of lots of rejections. I feel your suggestion would be beneficial for me. I will let you know if its function for me too. 362246
798940 913663I genuinely enjoy your website, but Im having a difficulty: any time I load one of your post in Firefox, the center of the internet page is screwed up – which is bizarre. Might I send you a screenshot? In any event, maintain up the superior work; I surely like reading you. 243603
796357 849779Merely wanna state that this is very beneficial , Thanks for taking your time to write this. 393925
36334 374410I conceive this site contains some rattling superb data for every person : D. 311079
56114 800794I like this web site really considerably so much superb info. 504691
352346 653529This constantly amazes me exactly how weblog owners for example yourself can locate the time and also the commitment to keep on composing fantastic weblog posts. Your site isexcellent and 1 of my own ought to read blogs. I merely want to thank you. 621173
291112 110999Hello there! I could have sworn Ive been to this blog before but soon after reading by way of some with the post I realized it is new to me. Anyhow, Im certainly pleased I discovered it and Ill be book-marking and checking back regularly! 961883